Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Azitra (NYSE American: AZTR) will present at Biotech Showcase in San Francisco on January 13, 2026 at 2:30 PM PT.
Rhea-AI Summary
Azitra (NYSE American: AZTR) will present at Biotech Showcase in San Francisco on January 13, 2026 at 2:30 PM PT. Management will hold one-on-one meetings with registered investors and potential partners to review the company's clinical development strategy, recent corporate achievements, and anticipated milestones.
The presentation will be delivered by Travis Whitfill, Chief Operating Officer, at the Hilton San Francisco Union Square (Yosemite C, Ballroom Level). Registration is available through the event website for accredited attendees.
Details
News Market Reaction – AZTR
On Jan 7, the day this news came out, AZTR closed 6.85% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference dates
- January 12–14, 2026
- Biotech Showcase 2026 in San Francisco
- Presentation time
- January 13, 2026, 2:30 PM PT
- Azitra presentation at Biotech Showcase 2026
- Current price
- $0.2845
- Pre-news trading level for AZTR
- 52-week high
- $4.329
- Pre-news 52-week range high
- 52-week low
- $0.26
- Pre-news 52-week range low
- Market cap
- $3,047,136
- Pre-news equity value
- 20-day avg volume
- 329,218 shares
- Liquidity benchmark pre-announcement
- Today’s volume
- 215,252 shares
- Same-day trading before/around conference news
Historical Context
-
Exchange accepted equity compliance plan but highlighted delisting risk and monitoring.
-
Completed $1.5M private placement with warrants at $0.32 offering price.
-
Reported Q3 2025 results, pipeline progress and low cash balance details.
-
Denied false report about a $44M registered direct offering announcement.
-
Reported positive preclinical data for ATR-01 ichthyosis vulgaris program.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
During the event, members of Azitra's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's clinical development strategy, recent corporate achievements, and anticipated milestones.
Details are as follows:
Event: | Biotech Showcase 2026 |
Date & Time | Tuesday, January 13, 2026, 2:30 PM, PT |
Location: | Hilton San Francisco Union Square, Yosemite C (Ballroom Level) |
Presenter | Travis Whitfill, Chief Operating Officer |
Registration: | https://informaconnect.com/biotech-showcase/registration-options/ |
About Azitra, Inc.
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adults with Netherton syndrome. ATR-04, Azitra's additional clinical program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated skin toxicity; a Phase 1/2 clinical trial has been initiated for this program. Azitra has received Fast Track designation from the United States Food and Drug Administration for this program to treat EGFRi associated rash, which impacts approximately 150,000 people in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Company's ability to satisfy closing conditions for the offering, the expected timing of (i) our provision of initial safety data and topline results for the phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and (iv) statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the satisfaction of the conditions to closing of the private placement, the timing of clinical trials and their results as we may experience delays in the provision of initial safety data and topline results for ATR-12 or, if we do, that such data may not be favorably received; the safety and efficacy of our product candidates; possible delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-to-present-at-biotech-showcase-alongside-the-jp-morgan-annual-healthcare-conference-302654475.html
SOURCE Azitra, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.